Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial

Next Previous
X
Search
Trial Profile

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alteplase (Primary) ; Dalteparin sodium; Enoxaparin sodium; Heparin; Tinzaparin sodium; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTRACT

    • Most Recent Events

    • 15 Jan 2021 Results of post-hoc analysis of the ATTRACT pharmacomechanical catheter-directed thrombolysis (PCDT) trial, assessing the effects of PCDT on VEINES quality of life and Villalta scores for specific symptom onset to randomization timeframes, published in the Circulation
    • 30 Jan 2019 Results published in the Thrombosis and Haemostasis
    • 07 Dec 2017 Primary endpoint (Cumulative incidence of Post-Thrombotic Syndrome (Villalta Scale)) has not been met as per the results published in the New England Journal of Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top